Skip to main content
Open Access Publications from the University of California


UC San Francisco Previously Published Works bannerUCSF

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

  • Author(s): Dahiya, Rajvir
  • Arichi, N
  • Mitsui, Y
  • Hiraki, M
  • Nakamura, S
  • Hiraoka, T
  • Sumura, M
  • Hirata, H
  • Tanaka, Y
  • Yasumoto, H
  • et al.

Published Web Location
No data is associated with this publication.

In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item